Skip to main content
. 2014 Nov 25;57(23):10192–10197. doi: 10.1021/jm501375c

Figure 3.

Figure 3

Molecular pharmacology of (S)-9b. (A) CRC of (S)-9b in the presence and absence of an EC20 of GLP-1 (EC50 = 1.8 μM, pEC50 = 5.74 ± 0.2, 59.2 ± 2% GLP-1 max). (B) CRC of (S)-9b in the presence and absence of an EC20 of 1 (EC50 = 8.4 μM, pEC50 = 5.07 ± 0.3, 71.5 ± 5% 1 max). (C) CRC of (S)-9b in the presence and absence of an EC20 of 2 (EC50 = 30 μM, pEC50 = 4.5 ± 0.2, 59.2 ± 1% 1 max). (D) Fold-shift experiment of GLP-1 in the presence of increasing concentrations of (S)-9b, with a maximum fold-shift of 1.6-fold at 20 μM.